The device is designed to imitate the bifurcation of the trachea in order to enable safer lung isolation and single-lung ventilation to help doctors reduce the risk of dislocation during surgery.
"We believe the EZ-Blocker endobronchial blocker is the most innovative bronchial blocker available and has the potential to improve patient outcomes during difficult procedures," said Cary Vance, president of the Teleflex anesthesia and respiratory division, in prepared remarks. "The availability of this product in the U.S. market will allow Teleflex to further its partnership with clinicians in improving patient safety and enhancing procedural efficiency."
The approval will enhance Teleflex’s airway management portfolio, which includes its differentiated Rusch and Sheridan brands of endotracheal and endobronchial products, the company said.
The EZ-Blocker Endobronchial Blocker previously had the CE mark approval in Europe.
As of about 1:45 p.m. today, TFX stock values declined 0.35% to $68.58.